Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 1/20 | 0.63 |
| ▸ | CTSL | P07711 | 1/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10513049 | 1.00 | CTSV (0.63) | CTSVCTSLBCHELOXL2MTNR1A | |
| SCHEMBL31454125 | 1.00 | CTSV (0.63) | CTSVCTSLBCHELOXL2MTNR1A | |
| SCHEMBL287067 | 1.00 | CTSV (0.63) | CTSVCTSLBCHELOXL2MTNR1A | |
| SCHEMBL10513013 | 1.00 | CTSV (0.63) | CTSVCTSLBCHELOXL2MTNR1A | |
| SCHEMBL31041747 | 1.00 | CTSV (0.63) | CTSVCTSLBCHELOXL2MTNR1A | |
| SCHEMBL3702698 | 1.00 | CTSV (0.63) | CTSVCTSLBCHELOXL2MTNR1A | |
| SCHEMBL11415263 | 1.00 | CTSV (0.63) | CTSVCTSLBCHELOXL2MTNR1A | |
| Methane SCHEMBL27817441 | 0.98 | CTSV (0.61) | CTSVCTSLBCHELOXL2MTNR1A | |
| SCHEMBL28774442 | 0.98 | CTSV (0.61) | CTSVCTSLBCHELOXL2MTNR1A | |
| SCHEMBL30382957 | 0.98 | CTSV (0.60) | CTSVCTSLBCHELOXL2MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111630155-B | Islet cell preparation compositions and methods of use | 沃泰克斯药物股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-116981466-A | Stem cell differentiation and polymers | 沃泰克斯药物股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-109970619-B | Indolethiodiene type metal complex and preparation method thereof | 沈阳师范大学 | 2022-06-28 | — | — | CN | disclosed |
| US-9464048-B2 | 5-oxo-ETE receptor antagonist compounds | FLORIDA INSTITUTE OF TECHNOLOGY (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140323535-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-10-30 | — | — | US | disclosed |
| EP-2427430-B1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | UNIV MCGILL (CA) | 2014-09-10 | — | — | EP | disclosed |
| US-8809382-B2 | 5-oxo-ETE receptor antagonist compounds | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2014-08-19 | — | — | US | disclosed |
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | FLORIDA INSTITUTE OF TECHNOLOGY | 2012-05-17 | — | — | US | disclosed |
| EP-1322646-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | Novuspharma S.p.A. (IT) | 2003-07-02 | — | — | EP | disclosed |
| EP-1244652-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | Cell Therapeutics Europe S.R.L. (IT) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002008225-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001047916-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122942-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | OXER1, PTGIR, EDNRA | CTSV 1540/4885CTSL 1135/4885BCHE 1513/4885 |
| US-20140323535-A1 | 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS | OXER1, PTGIR, EDNRA | CTSV 1540/4885CTSL 1135/4885BCHE 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.